Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).

abstract：:Acute myocardial infarction (AMI) recognises no boundaries, and the patient's greatest need occurs at the interface between primary care and hospital system. Ideally, the general practitioner, if summoned, should be able to provide resuscitation, analgesia with opiates, and thrombolytic therapy. Thrombolytics should c...

journal_title：Drugs

authors： Rawles J

更新日期：1995-10-01 00:00:00

abstract：:Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...

journal_title：Drugs

authors： Scott LJ,Keam SJ

更新日期：2021-01-06 00:00:00

abstract：:Arrhythmia treatment has always been difficult, particularly as there are no good indicators of the optimal management strategy. The introduction of new antiarrhythmic agents has forced reappraisal of how these drugs are used. Dynamic electrocardiography and invasive electrophysiological studies are important tools fo...

journal_title：Drugs

authors： Campbell RW

更新日期：1988-11-01 00:00:00

abstract：:Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine ...

journal_title：Drugs

authors： Greig SL

更新日期：2015-09-01 00:00:00

abstract：:We have analysed the published literature on eptacog alfa (recombinant factor VIIa; rFVIIa) for nonhaemophiliac conditions with the aim of determining its current place in therapy. Initial surgical and/or medical management is required for any patient with life-threatening bleeding. In those with continued life-threat...

journal_title：Drugs

authors： Mallarkey G,Brighton T,Thomson A,Kaye K,Seale P,Gazarian M

更新日期：2008-01-01 00:00:00

abstract：:Rupatadine (Rupafin, Rinialer, Rupax, Alergoliber) is a selective oral histamine H(1)-receptor antagonist that has also been shown to have platelet-activating factor (PAF) antagonist activity in vitro. It is indicated for use in seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR) and chronic idiopathic...

journal_title：Drugs

authors： Keam SJ,Plosker GL

更新日期：2007-01-01 00:00:00

abstract：:There are several first choices for the treatment of mild and moderate hypertension. The selection of a drug may be influenced by concomitant pathology, with positive indications for particular drugs, e.g. coexistent angina, indicating use of a beta-receptor blocking drug or calcium antagonist; fluid retention indicat...

journal_title：Drugs

authors： Prichard BN

更新日期：1988-01-01 00:00:00

abstract：:All 27 EU member states and another seven countries participate in the European Surveillance of Antimicrobial Consumption (ESAC) project. ESAC carried out three hospital point-prevalence surveys on antimicrobial use. Point-prevalence surveys linked antimicrobial use to indication and also assessed dosing using a stand...

journal_title：Drugs

authors： Zarb P,Goossens H

更新日期：2011-04-16 00:00:00

abstract：:Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor antagonist. Intravenous tocilizumab 8 mg/kg (and no less than 4.8 mg), in combination with methotrexate, is approved in the EU for the treatment of moderate to severe active rheumatoid arthriti...

journal_title：Drugs

authors： Oldfield V,Dhillon S,Plosker GL

更新日期：2009-01-01 00:00:00

abstract：:Multiple drugs are now available for the treatment of overactive bladder. Currently, the pharmacological approach is to deal with the problem at the neuromuscular junction by attempting to stop the activity of the neurotransmitter with antimuscarinic medications. This article reviews the positive and negative aspects ...

journal_title：Drugs

authors： Appell RA

更新日期：2006-01-01 00:00:00

abstract：:The bacteria most commonly responsible for early-onset (materno-fetal) infections in neonates are group B streptococci, enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are the main pathogens in late-onset (nosocomial) infections, es...

journal_title：Drugs

authors： Fanos V,Dall'Agnola A

更新日期：1999-09-01 00:00:00

abstract：:Trimetrexate is a folinic acid analogue structurally related to methotrexate, whose primary mechanism of action is believed to be inhibition of dihydrofolate reductase. This reduces the production of DNA and RNA precursors and leads to cell death. Trimetrexate is lipophilic and can passively diffuse across cell membra...

journal_title：Drugs

authors： Fulton B,Wagstaff AJ,McTavish D

更新日期：1995-04-01 00:00:00

abstract：:Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites whi...

journal_title：Drugs

authors： Brogden RN,Heel RC,Pakes GE,Speight TM,Avery GS

更新日期：1979-11-01 00:00:00

abstract：:Purine nucleoside analogues are a new class of drugs with activity against nondividing lymphocytes; thus, they should play a major role in the treatment of low grade lymphoid malignancies. As these drugs are active against resting lymphocytes, harmful effects related to this action were expected and have been reported...

journal_title：Drugs

authors： Dighiero G

更新日期：1994-01-01 00:00:00

abstract：:The lipid-modifying profile of bezafibrate is characterised by marked decreases in elevated triglyceride levels, increases in high density lipoprotein (HDL) cholesterol levels and decreases in total and low density lipoprotein (LDL) cholesterol levels. Bezafibrate also reduces elevated levels of lipoprotein(a) [Lp(a)]...

journal_title：Drugs

authors： Goa KL,Barradell LB,Plosker GL

更新日期：1996-11-01 00:00:00

abstract：:The comprehensive treatment of schizophrenia requires the full resources of a clinical team that is able to offer treatment for the acute psychotic state in a hospital environment, and appropriate rehabilitation following resolution of the florid symptoms. Following a second or subsequent relapse, maintenance therapy ...

journal_title：Drugs

authors： Johnson DA

更新日期：1977-10-01 00:00:00

abstract：:Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in...

journal_title：Drugs

authors： Markham A,Keam SJ

更新日期：2019-06-01 00:00:00

abstract：:Suvorexant (Belsomra(®)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neuro...

journal_title：Drugs

authors： Yang LP

更新日期：2014-10-01 00:00:00

abstract：:Zimelidine is a new antidepressant, which is structurally unrelated to the tricyclic and tetracyclic antidepressants. The pharmacological profile of zimelidine is different to that of other antidepressants in that it appears to owe the major part of its activity to the inhibition of serotonin uptake within the central...

journal_title：Drugs

authors： Heel RC,Morley PA,Brogden RN,Carmine AA,Speight TM,Avery GS

更新日期：1982-09-01 00:00:00

abstract：:Schistosomiasis, a grave and debilitating disease of socioeconomic importance, is increasing in incidence despite concerted efforts to control and contain the disease in all the endemic areas. While a multipronged method of control using health education, sanitation and snail control has been used, chemotherapy and ch...

journal_title：Drugs

authors： Shekhar KC

更新日期：1991-09-01 00:00:00

abstract：:Safety data have been gathered in US clinical trials of nabumetone on 1912 patients from August 1981 to May 1988. Dosing in the double-blind trials was 100 mg at bedtime, but in open-label trials patients could increase the dosage of nabumetone to 1500 or 2000 mg if required. Adverse experiences reported in the double...

journal_title：Drugs

authors： Willkens RF

更新日期：1990-01-01 00:00:00

abstract：:Lanreotide Autogel (ATG) [Somatuline Depot] is a novel, long-acting preparation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most...

journal_title：Drugs

authors： Croxtall JD,Scott LJ

更新日期：2008-01-01 00:00:00

abstract：:Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...

journal_title：Drugs

authors： Dhillon S

更新日期：2020-03-01 00:00:00

abstract：:Rapid progress has recently been encountered in pharmacologically treating the unborn baby. This unique area of drug therapy raises new methodological and ethical questions. This article is a systematic review of known modalities of fetal pharmacotherapy, and aims to highlight essential principles, difficulties and co...

journal_title：Drugs

authors： Koren G,Klinger G,Ohlsson A

更新日期：2002-01-01 00:00:00

abstract：:Vitamin A acid (retinoic acid: tretinoin) is a vitamin A derivative used in the topical treatment of acne. It acts by 'unseating' comedones, improvement developing slowly over a period of 2 to 3 or more months, and is also said to prevent the formation of new lesions. About three-quarters of patients with acne vulgari...

journal_title：Drugs

authors： Heel RC,Brogden RN,Speight TM,Avery GS

更新日期：1977-12-01 00:00:00

abstract：:Preclinical studies indicate that angiogenic growth factors can stimulate the development of collateral arteries in animal models of peripheral or myocardial ischaemia, a concept termed 'therapeutic angiogenesis'. The goal of this review is to provide a brief overview of the advantages and disadvantages of gene versus...

journal_title：Drugs

authors： Amant C,Berthou L,Walsh K

更新日期：1999-01-01 00:00:00

abstract：:In the 30 years since the rabbit antithymocyte globulin (rATG) Thymoglobulin(®) was first licensed, its use in solid organ transplantation and hematology has expanded progressively. Although the evidence base is incomplete, specific roles for rATG in organ transplant recipients using contemporary dosing strategies are...

journal_title：Drugs

authors： Mohty M,Bacigalupo A,Saliba F,Zuckermann A,Morelon E,Lebranchu Y

更新日期：2014-09-01 00:00:00

abstract：:Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of bone tissue. These changes lead to an increase in bone fragility and an increased risk for fracture, which are the clinical consequences of osteoporosis. The classical triad...

journal_title：Drugs

authors： Reginster JY

更新日期：2011-01-01 00:00:00

abstract：:The current challenge facing clinicians is to develop pharmacotherapies that move beyond the treatment of symptoms towards a new agenda in cardiovascular therapeutics that includes interventions to actually prevent the development of end-stage coronary heart disease. The development of new strategies to alter the natu...

journal_title：Drugs

authors： Gibbons GH

更新日期：1997-01-01 00:00:00

abstract：:Fluticasone furoate nasal spray is a new topical intranasal corticosteroid with enhanced affinity for the glucocorticoid receptor and low systemic exposure, which was recently approved in the US for the treatment of seasonal or perennial allergic rhinitis in adults and in children aged >or=2 years. Fluticasone furoate...

journal_title：Drugs

authors： McCormack PL,Scott LJ

更新日期：2007-01-01 00:00:00